alogliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dipeptidyl aminopeptidase-IV inhibitors 4340 850649-61-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vipidia
  • alogliptin
  • alogliptin benzoate
  • nesina
a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4) that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
  • Molecular weight: 339.40
  • Formula: C18H21N5O2
  • CLOGP: 1.27
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 93.67
  • ALOGS: -2.77
  • ROTB: 3

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 25, 2013 FDA TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 81.27 26.11 22 1729 5885 50597488
Cerebral infarction 46.59 26.11 20 1731 21584 50581789
Pancreatic carcinoma 44.74 26.11 14 1737 6200 50597173
Erythema multiforme 35.80 26.11 13 1738 9037 50594336
Interstitial lung disease 27.28 26.11 19 1732 53157 50550216
Hypoglycaemic encephalopathy 26.28 26.11 5 1746 273 50603100

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 176.57 22.68 52 2507 7529 29564439
Cerebral infarction 73.79 22.68 38 2521 24637 29547331
Pancreatitis acute 51.90 22.68 30 2529 24355 29547613
Pancreatitis 47.05 22.68 32 2527 34482 29537486
Spondylolysis 43.94 22.68 7 2552 49 29571919
Diabetic ketoacidosis 43.01 22.68 23 2536 16050 29555918
Interstitial lung disease 42.29 22.68 37 2522 57681 29514287
Lumbosacral radiculoplexus neuropathy 38.91 22.68 6 2553 33 29571935
Gastric cancer 32.23 22.68 13 2546 4781 29567187
Application site haematoma 29.89 22.68 5 2554 49 29571919
Hypoglycaemia 29.53 22.68 28 2531 48318 29523650
Tonsil cancer 28.88 22.68 8 2551 923 29571045
Glycosylated haemoglobin increased 23.84 22.68 13 2546 9413 29562555
Altered state of consciousness 23.70 22.68 17 2542 19872 29552096
Angina pectoris 22.70 22.68 19 2540 27831 29544137

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 252.82 19.84 74 4456 12912 64481290
Cerebral infarction 113.33 19.84 56 4474 40988 64453214
Pancreatitis acute 69.25 19.84 41 4489 42814 64451388
Interstitial lung disease 68.68 19.84 56 4474 97676 64396526
Diabetic ketoacidosis 57.42 19.84 32 4498 29813 64464389
Pancreatitis 52.36 19.84 39 4491 59568 64434634
Pancreatic carcinoma 50.36 19.84 21 4509 10352 64483850
Gastric cancer 45.00 19.84 17 4513 6476 64487726
Spondylolysis 40.87 19.84 7 4523 100 64494102
Hypoglycaemia 40.29 19.84 40 4490 89852 64404350
Euglycaemic diabetic ketoacidosis 36.90 19.84 14 4516 5396 64488806
Lumbosacral radiculoplexus neuropathy 36.40 19.84 6 4524 67 64494135
Lactic acidosis 32.57 19.84 30 4500 61380 64432822
Erythema multiforme 30.63 19.84 17 4513 15684 64478518
Hepatic function abnormal 29.51 19.84 29 4501 64284 64429918
Application site haematoma 29.09 19.84 5 4525 73 64494129
Altered state of consciousness 27.17 19.84 22 4508 37880 64456322
Tonsil cancer 25.57 19.84 7 4523 953 64493249
Colon cancer 25.42 19.84 14 4516 12725 64481477
Glycosylated haemoglobin increased 25.00 19.84 15 4515 16004 64478198
Blood glucose increased 22.58 19.84 31 4499 98042 64396160
Angina pectoris 21.93 19.84 21 4509 45060 64449142
Drug eruption 21.82 19.84 19 4511 36117 64458085
Hepatocellular carcinoma 21.78 19.84 11 4519 8392 64485810
Rhabdomyolysis 21.13 19.84 29 4501 91697 64402505
Drug-induced liver injury 20.95 19.84 21 4509 47622 64446580

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD09 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BH04 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Dipeptidyl peptidase 4 (DPP-4) inhibitors
MeSH PA D054873 Dipeptidyl-Peptidase IV Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D054795 Incretins
MeSH PA D011480 Protease Inhibitors
FDA MoA N0000175912 Dipeptidyl Peptidase 4 Inhibitors
FDA EPC N0000175913 Dipeptidyl Peptidase 4 Inhibitor
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:68612 dipeptidyl peptidase-4 inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.4 Basic
pKa2 1.33 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 12.5MG BASE;EQ 15MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;EQ 45MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE;EQ 15MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE;EQ 45MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL 8173663 Dec. 2, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL 8173663 Dec. 2, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 6.25MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL 8173663 Dec. 2, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 6.25MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 15MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 45MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 15MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 45MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Dipeptidyl peptidase 4 Enzyme INHIBITOR IC50 9 CHEMBL CHEMBL

External reference:

IDSource
4032098 VUID
N0000186570 NUI
D06553 KEGG_DRUG
850649-62-6 SECONDARY_CAS_RN
4032097 VANDF
4032098 VANDF
C1958126 UMLSCUI
CHEBI:72323 CHEBI
T22 PDB_CHEM_ID
CHEMBL376359 ChEMBL_ID
CHEMBL227529 ChEMBL_ID
DB06203 DRUGBANK_ID
C520853 MESH_SUPPLEMENTAL_RECORD_UI
6319 IUPHAR_LIGAND_ID
8814 INN_ID
JHC049LO86 UNII
11450633 PUBCHEM_CID
1368000 RXNORM
198438 MMSL
237036 MMSL
29087 MMSL
d07963 MMSL
014872 NDDF
014873 NDDF
702799001 SNOMEDCT_US
702800002 SNOMEDCT_US
703669009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 45802-087 TABLET, FILM COATED 6.25 mg ORAL NDA authorized generic 28 sections
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 45802-103 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 28 sections
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 45802-150 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 28 sections
alogliptin and metformin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 45802-169 TABLET, FILM COATED 12.50 mg ORAL NDA 29 sections
alogliptin and metformin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 45802-211 TABLET, FILM COATED 12.50 mg ORAL NDA 29 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-238 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 30 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-260 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 30 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-304 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 30 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-351 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 30 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-402 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 30 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-499 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 30 sections
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5574 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 27 sections
alogliptin and metformin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 50090-5993 TABLET, FILM COATED 12.50 mg ORAL NDA 28 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-121 TABLET, FILM COATED 12.50 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-121 TABLET, FILM COATED 12.50 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-123 TABLET, FILM COATED 12.50 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-123 TABLET, FILM COATED 12.50 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-124 TABLET, FILM COATED 12.50 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-124 TABLET, FILM COATED 12.50 mg ORAL NDA 31 sections
Nesina HUMAN PRESCRIPTION DRUG LABEL 1 64764-125 TABLET, FILM COATED 12.50 mg ORAL NDA 27 sections
Nesina HUMAN PRESCRIPTION DRUG LABEL 1 64764-125 TABLET, FILM COATED 12.50 mg ORAL NDA 27 sections
Nesina HUMAN PRESCRIPTION DRUG LABEL 1 64764-250 TABLET, FILM COATED 25 mg ORAL NDA 27 sections
Nesina HUMAN PRESCRIPTION DRUG LABEL 1 64764-250 TABLET, FILM COATED 25 mg ORAL NDA 27 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-251 TABLET, FILM COATED 25 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-251 TABLET, FILM COATED 25 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-253 TABLET, FILM COATED 25 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-253 TABLET, FILM COATED 25 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-254 TABLET, FILM COATED 25 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-254 TABLET, FILM COATED 25 mg ORAL NDA 31 sections
KAZANO HUMAN PRESCRIPTION DRUG LABEL 2 64764-335 TABLET, FILM COATED 12.50 mg ORAL NDA 30 sections